Kraft Heinz Recalls Capri Sun Wild Cherry Flavored Beverages

Kraft Heinz is recalling around 5,760 cases of Capri Sun Wild Cherry Flavored Juice Drink Blend beverages due to potential for chemical contaminants, the U.S. Food and Drug Administration said.

The recall involves 6.6 FL OZ Capri Sun Wild Cherry Flavored Juice Drink Blend in individual foil pouches packed in paperboard cartons. The Carton UPC is 0 8768400100 4, and case UPC is 87684 00409 00.

The “Best When Used By” date on the products is June 25, 2023.

The affected cases shipped to retailers include 4 cartons that are shrink-wrapped together. Product is sold by the carton at retail.

The agency noted that the diluted cleaning solution, which is used on food processing equipment, was inadvertently introduced into a production line at one of the company’s factories.

The recall was initiated after receiving several consumer complaints about the taste of the affected product.

Only the Wild Cherry flavored Capri Sun products with the particular case/package information is included in the recall.

Consumers who purchased these items are urged to return it to the store where it was purchased.

For More Such Health News, visit rttnews.com

GSK: FDA Accepts New Drug Application For Momelotinib To Treat Myelofibrosis

British drug maker GSK plc (GSK,GSK.L) announced Wednesday that the US Food and Drug Administration accepted the New Drug Application or NDA for momelotinib for the treatment of myelofibrosis.

Myelofibrosis is a rare blood cancer that results from dysregulated JAK-signal transducer and activator of transcription protein signalling. It is characterised by constitutional symptoms, splenomegaly, and progressive anaemia.

Momelotinib is a potential new medicine with a proposed differentiated mechanism of action that may address the significant unmet medical needs of myelofibrosis patients with anaemia. Momelotinib is not currently approved in any market.

The FDA has assigned a Prescription Drug User Fee Act action date of June 16, 2023.

The company noted that the NDA is based on the results from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary endpoints. These included Total Symptom Score or TSS, Transfusion Independence or TI rate and Splenic Response Rate or SRR.

The primary analysis data from the MOMENTUM trial were recently presented at the 2022 American Society of Clinical Oncology Annual Meeting and the European Hematology Association 2022 Hybrid Congress.

Momelotinib was most recently developed by Sierra Oncology, Inc., which GSK acquired in July 2022.

For More Such Health News, visit rttnews.com

Britons urged to ‘lock in mortgage rate now’ as inflation soars – beware ‘word of caution’

We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info

Samuel Mather-Holgate of Swindon-based advisory firm, Mather & Murray Financial, said: “If you have a mortgage, or are looking to borrow some money, my advice would be to lock in your rate now.

“If you prefer certainty, lock in for a long period as interest rates are still historically low, despite them increasing.

“A word of caution though; when inflation falls back to normal levels, in six months time, and the recession is in full swing, the Bank of England will be forced to cut interest rates. We just don’t know by how much yet.”

More to follow…

Hochschild Mining Posts HY Loss

Hochschild Mining plc (HOC.L) reported that its loss from continuing operations attributable to equity shareholders of the parent for six months ended 30 June 2022 was $2.77 million or $0.01 per share compared to net income of $34.73 million or $0.07 per share in the prior year.

Gross revenue from continuing operations for the period decreased 12% to $354.7 million from the prior year’s $404.4 million due to the lower average realised silver prices, and lower silver and gold production. Output was mainly impacted by lower grades in Pallancata, and lower treated tonnage in San Jose due to Covid-related employee absences and a fire in the crushing area which temporarily affected operations. These were partially offset by a higher average realised gold price.

The company remains on track to meet its overall attributable production target for 2022 of 360,000-375,000 gold equivalent ounces or 26.0-27.0 million silver equivalent ounces.

Hochschild Mining declared an interim dividend of 1.95 cents per share ($10.0 million).

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Al Franken Becomes First Former U.S. Senator to Host ‘Jimmy Kimmel Live’

“But tonight is not about politics, it’s about comedy and having fun,” he said. “So, who’s here from out of state to get an abortion?”

Send any friend a story

As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.

By Trish Bendix

Plus500 H1 Net Profit Rises; Revenue Up 48%

Plus500 Ltd. (PLUS.L) reported that its first-half net profit increased to $244.1 million from $165.1 million, prior year. Earnings per share was $2.43 compared to $1.61. EBITDA was $305.3 million compared to $187.6 million.

Customer income was at $339.8 million compared to $379.2 million, a year ago. Customer trading performance was $171.6 million during first half of 2022. Total revenue increased to $511.4 million from $346.2 million.

Looking forward, the Board of Plus500 remains optimistic about the Group’s performance, with sustainable growth to be delivered over the medium to long term.

The Board declared a total return of $120.4 million in relation to first half 2022, comprising of an interim dividend and a new share buyback programme. The interim dividend for first half 2022 of $60.2 million, representing $0.6238 per share, has an ex-dividend date of 25 August 2022, a record date of 26 August 2022 and a payment date of 11 November 2022. The Board has resolved to conduct a new share buyback programme to acquire up to $60.2 million of the company’s shares.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.